



OFFICERS

President

Richard G. Harris, MD
Melrose Park, IL

President-Elect

Jonathan Henderson, MD
Shreveport, LA

Secretary

Evan Goldfischer, MD, MBA, CPE
Poughkeepsie, NY

Treasurer

Robert D. Asinof, MSHA
Denver, CO

Past President

Neal D. Shore, MD
Myrtle Beach, SC

BOARD OF DIRECTORS

David M. Albala, MD, FACS
Syracuse, NY

E. Scot Davis, MPA, MBA, CMPE
Little Rock, AR

David J Ellis, MD, FACS
Rosemont, PA

Michael D. Fabrizio, MD, FACS
Virginia Beach, VA

Mara R. Holton, MD
Annapolis, MD

Scott B. Sellinger, MD
Tallahassee, FL

Jeffrey M. Spier, MD
El Paso, TX

Alan D. Winkler, MHSA, FACMPE
San Antonio, TX

Chief Executive Officer

Celeste G. Kirschner, CAE

875 N. Michigan Avenue
Suite 3100
Chicago, IL 60611
www.lugpa.org



February 11, 2020

Honorable Bobby L. Rush
Honorable Larry Bucshon
U.S. House of Representatives
Washington, DC 20515

Dear Reps. Rush and Bucshon,

On behalf of the over 2,200 physicians representing 154 urology group practices across the United States who collectively provide nearly 40% of the nation's urology services, we write to offer our strong support for H.R. 5200, the PSA Screening for HIM Act. LUGPA's physicians are on the front lines helping what the American Cancer Society estimated was approximately 174,650 men diagnosed with prostate cancer in 2019.

The PSA Screening for HIM Act is critically important as the number of deaths due to prostate cancer has been increasing – prostate cancer is now the second highest cancer-related cause of death in the United States. Tragically, many of these lives would not have been lost had the cancer been detected early. The goal of your legislation is laudable as it will increase access to prostate cancer screenings by eliminating cost-sharing requirements to patients.

Removing barriers to screening for those at a high risk of developing prostate cancer is a critical component of this legislation. High risk groups include African American men, those with a family history of prostate cancer as well as our nation's servicemen who may have suffered toxin exposure. Waiving cost-sharing (including deductibles, copayments and coinsurances) for these groups will help millions of men secure an early diagnosis and seek treatment for this potentially deadly disease.

Once again, on behalf of our patients and our physicians, we thank you for sponsoring this important legislation and we look forward to working with you to ensure its passage.

Sincerely,

Richard G. Harris, M.D.
President

Deepak A. Kapoor, M.D.
Chairman, Health Policy